FDA approves lurbinectedin in combination with atezolizumab for extensive-stage small cell lung cancer.
The recent FDA approval of lurbinectedin plus atezolizumab for advanced small cell lung cancer underscores the promise of combining immunogenic cell death (ICD) inducers with PD-1/PD-L1 blockade.
APA
Kepp O, Kroemer G (2025). FDA approves lurbinectedin in combination with atezolizumab for extensive-stage small cell lung cancer.. Oncoimmunology, 14(1), 2584898. https://doi.org/10.1080/2162402X.2025.2584898
MLA
Kepp O, et al.. "FDA approves lurbinectedin in combination with atezolizumab for extensive-stage small cell lung cancer.." Oncoimmunology, vol. 14, no. 1, 2025, pp. 2584898.
PMID
41254986
Abstract
The recent FDA approval of lurbinectedin plus atezolizumab for advanced small cell lung cancer underscores the promise of combining immunogenic cell death (ICD) inducers with PD-1/PD-L1 blockade. This synergistic strategy induces durable responses in refractory tumors and may extend immunotherapy benefits across diverse malignancies through rational ICD-checkpoint inhibitor combinations.
MeSH Terms
Humans; Small Cell Lung Carcinoma; Lung Neoplasms; Antibodies, Monoclonal, Humanized; Carbolines; Antineoplastic Combined Chemotherapy Protocols; Drug Approval; United States; Heterocyclic Compounds, 4 or More Rings; United States Food and Drug Administration; Heterocyclic Compounds, 3-Ring; Neoplasm Staging